


<OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
         xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
    <responseDate>2025-09-09T13:52:50Z</responseDate>
    <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:12406680" metadataPrefix="pmc">https://pmc.ncbi.nlm.nih.gov/api/oai/v1/mh/</request>
    
    <GetRecord>
        <record>
    <header>
    <identifier>oai:pubmedcentral.nih.gov:12406680</identifier>
    <datestamp>2025-09-04</datestamp>
    
        
        <setSpec>aac</setSpec>
        
    
        
        <setSpec>pmc-open</setSpec>
        
    
</header>
    <metadata>
        
        <article xmlns="https://jats.nlm.nih.gov/ns/archiving/1.4/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.4/ https://jats.nlm.nih.gov/archiving/1.4/xsd/JATS-archivearticle1-4.xsd" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Antimicrob Agents Chemother</journal-id><journal-id journal-id-type="iso-abbrev">Antimicrob Agents Chemother</journal-id><journal-id journal-id-type="pmc-domain-id">82</journal-id><journal-id journal-id-type="pmc-domain">aac</journal-id><journal-id journal-id-type="publisher-id">aac</journal-id><journal-title-group><journal-title>Antimicrobial Agents and Chemotherapy</journal-title></journal-title-group><issn pub-type="ppub">0066-4804</issn><issn pub-type="epub">1098-6596</issn><publisher><publisher-name>American Society for Microbiology (ASM)</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12406680</article-id><article-id pub-id-type="pmcid-ver">PMC12406680.1</article-id><article-id pub-id-type="pmcaid">12406680</article-id><article-id pub-id-type="pmcaiid">12406680</article-id><article-id pub-id-type="pmid">40757817</article-id><article-id pub-id-type="doi">10.1128/aac.00462-25</article-id><article-id pub-id-type="publisher-id">aac00462-25</article-id><article-id pub-id-type="publisher-id">aac.00462-25</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Pharmacology</subject></subj-group><subj-group subj-group-type="biological-terms"><compound-subject><compound-subject-part content-type="code">antimicrobial-chemotherapy</compound-subject-part><compound-subject-part content-type="label">Antimicrobial Chemotherapy</compound-subject-part></compound-subject></subj-group></article-categories><title-group><article-title>Pharmacokinetics, safety, and tolerability of onradivir in participants with severe renal impairment and matched healthy control participants</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0009-0007-7432-8454</contrib-id><name name-style="western"><surname>Li</surname><given-names initials="H">Haijun</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Funding acquisition" vocab-term-identifier="https://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Project administration" vocab-term-identifier="https://credit.niso.org/contributor-roles/project-administration/">Project administration</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review and editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review and editing</role></contrib><contrib contrib-type="author" equal-contrib="yes"><name name-style="western"><surname>Yang</surname><given-names initials="X">Xiali</given-names></name><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Project administration" vocab-term-identifier="https://credit.niso.org/contributor-roles/project-administration/">Project administration</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/contributor-roles/resources/">Resources</role></contrib><contrib contrib-type="author"><name name-style="western"><surname>Zhang</surname><given-names initials="J">Jun</given-names></name><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role></contrib><contrib contrib-type="author"><name name-style="western"><surname>Chen</surname><given-names initials="L">Lin</given-names></name><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Project administration" vocab-term-identifier="https://credit.niso.org/contributor-roles/project-administration/">Project administration</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/contributor-roles/resources/">Resources</role></contrib><contrib contrib-type="author"><name name-style="western"><surname>Zhou</surname><given-names initials="M">Mingfei</given-names></name><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role></contrib><contrib contrib-type="author"><name name-style="western"><surname>Li</surname><given-names initials="Y">Youyun</given-names></name><xref rid="aff4" ref-type="aff">
<sup>4</sup>
</xref><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Software" vocab-term-identifier="https://credit.niso.org/contributor-roles/software/">Software</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#8211; original draft</role></contrib><contrib contrib-type="author"><name name-style="western"><surname>Liu</surname><given-names initials="X">Xiangxing</given-names></name><xref rid="aff4" ref-type="aff">
<sup>4</sup>
</xref><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#8211; original draft</role></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-8496-2087</contrib-id><name name-style="western"><surname>Huang</surname><given-names initials="J">Jiyi</given-names></name><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="cor1" ref-type="corresp"/><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/contributor-roles/resources/">Resources</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review and editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review and editing</role><email>hjy0602@163.com</email></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-9161-1055</contrib-id><name name-style="western"><surname>Huang</surname><given-names initials="J">Jufang</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="cor2" ref-type="corresp"/><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review and editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review and editing</role><email>huangjufang@csu.edu.cn</email></contrib><aff id="aff1"><label>1</label><institution-wrap><institution>Department of Anatomy and Neurobiology, School of Basic Medical Sciences, Central South University</institution><institution-id institution-id-type="ringgold">618101</institution-id><institution-id institution-id-type="ror">https://ror.org/00f1zfq44</institution-id></institution-wrap>, <city>Changsha</city>, <country>China</country></aff><aff id="aff2"><label>2</label><institution-wrap><institution>Department of Nephrology, First Affiliated Hospital of Xiamen University</institution><institution-id institution-id-type="ringgold">117892</institution-id><institution-id institution-id-type="ror">https://ror.org/0006swh35</institution-id></institution-wrap>, <city>Xiamen</city>, <country>China</country></aff><aff id="aff3"><label>3</label><institution-wrap><institution>Phase 1 Clinical Unit, The First Affiliated Hospital of Jinan University</institution><institution-id institution-id-type="ringgold">162698</institution-id><institution-id institution-id-type="ror">https://ror.org/05d5vvz89</institution-id></institution-wrap>, <city>Guangzhou</city>, <country>China</country></aff><aff id="aff4"><label>4</label><institution-wrap><institution>Guangdong Raynovent Biotech Co., Ltd</institution><institution-id institution-id-type="ringgold">681093</institution-id></institution-wrap>, <city>Guangzhou</city>, <country>China</country></aff></contrib-group><contrib-group><contrib contrib-type="editor"><role>Editor</role><name name-style="western"><surname>Arias</surname><given-names initials="CA">Cesar A.</given-names></name><aff><institution-wrap><institution>Houston Methodist Hospital and Weill Cornell Medical College</institution></institution-wrap>, <city>Houston</city>, <state>Texas</state>, <country>USA</country></aff></contrib></contrib-group><author-notes><corresp id="cor1">Address correspondence to Jiyi Huang, <email xlink:href="mailto:hjy0602@163.com">hjy0602@163.com</email></corresp><corresp id="cor2">Address correspondence to Jufang Huang, <email xlink:href="mailto:huangjufang@csu.edu.cn">huangjufang@csu.edu.cn</email></corresp><fn fn-type="equal"><p>Haijun Li and Xiali Yang contributed equally to this article. Author order was determined in order of increasing seniority.</p></fn><fn fn-type="COI-statement"><p>H.L., Y.L., and X.L. are employees of Guangdong Raynovent Biotech Co., Ltd. All the other authors declare no conflict of interest.</p></fn></author-notes><pub-date publication-format="electronic" date-type="collection"><month>9</month><year>2025</year></pub-date><pub-date date-type="pub" publication-format="electronic"><day>04</day><month>8</month><year>2025</year></pub-date><volume>69</volume><issue>9</issue><issue-id pub-id-type="pmc-issue-id">496152</issue-id><elocation-id>e00462-25</elocation-id><history><date date-type="received"><day>20</day><month>3</month><year>2025</year></date><date date-type="accepted"><day>13</day><month>6</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>04</day><month>08</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>04</day><month>09</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-09-04 10:25:45.023"><day>04</day><month>09</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>Copyright &#169; 2025 Li et al.</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>Li et al.</copyright-holder><ali:free_to_read start_date="2025-08-04"/><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open-access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution 4.0 International license</ext-link>.</license-p></license></permissions><self-uri content-type="pmc-pdf" xlink:href="aac.00462-25.pdf"/><self-uri content-type="pdf" xlink:href="aac.00462-25.pdf"/><abstract abstract-type="primary"><title>ABSTRACT</title><p>Onradivir is an influenza A virus RNA polymerase basic protein 2 inhibitor that is currently under development for the treatment of influenza A. Renal impairment can influence drug absorption, metabolism, and transport, potentially altering the pharmacokinetics (PK) of onradivir. This study aimed to provide guidance on clinical dosing for patients with renal impairment by evaluating the impact of renal impairment on the PK, safety, and tolerability of onradivir in a nonrandomized, parallel, single-dose study. Participants with severe renal impairment (estimated glomerular filtration rate 15&#8211;29 mL/min) along with healthy participants (<italic toggle="yes">n</italic> = eight per group) received a single oral dose of 600 mg onradivir. All participants exhibited good safety and tolerability after oral administration of onradivir, with treatment-emergent adverse events being limited to mild or moderate severity. Compared to participants with normal renal function, the maximum plasma concentration (<italic toggle="yes">C</italic><sub>max</sub>) of onradivir in those with severe renal impairment was similar; however, the area under the plasma concentration time curve from zero to the last quantifiable concentration (AUC<sub>0<italic toggle="yes">&#8211;t</italic></sub>) and the AUC from zero to infinity (AUC<sub>0&#8211;inf</sub>) were slightly lower. The geometric mean ratios and 90% confidence intervals for <italic toggle="yes">C</italic><sub>max</sub>, AUC<sub>0&#8211;<italic toggle="yes">t</italic></sub>, and AUC<sub>0&#8211;inf</sub> were 101.35% (63.85%&#8211;160.86%), 76.31% (52.47%&#8211;110.97%), and 76.56% (51.02%&#8211;114.90%), respectively. Severe renal impairment did not have a clinically meaningful effect on the PK, tolerability, or safety of onradivir. Therefore, no dose adjustment is necessary for patients with mild-to-severe renal impairment who are taking onradivir.</p><sec><title>CLINICAL TRIALS</title><p>This study is registered with ClinicalTrials.gov as <related-object source-type="clinical-trials-registry" source-id-type="registry-name" source-id="ClinicalTrials.gov" document-id="NCT06248567" document-id-type="clinical-trial-number" xlink:href="https://clinicaltrials.gov/study/NCT06248567" id="RO1"><ext-link ext-link-type="pmc:clinical-trial" xlink:href="NCT06248567">NCT06248567</ext-link></related-object>.</p></sec></abstract><kwd-group><title>KEYWORDS</title><kwd>onradivir</kwd><kwd>influenza</kwd><kwd>pharmacokinetics</kwd><kwd>renal impairment</kwd></kwd-group><funding-group specific-use="FundRef"><award-group award-type="grant" id="award-1"><funding-source><institution-wrap><institution>Guangdong Raynovent Biotech Co., Ltd</institution></institution-wrap></funding-source><award-id>NA</award-id><principal-award-recipient><name name-style="western"><surname>Li</surname><given-names>Haijun</given-names></name></principal-award-recipient></award-group></funding-group><counts><count count="1" count-type="supplementary-material"/><count count-type="authors" count="9"/><fig-count count="2"/><table-count count="2"/><equation-count count="0"/><ref-count count="26"/><page-count count="11"/><word-count count="6006"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>September 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="s1"><title>INTRODUCTION</title><p>Influenza is an acute viral respiratory infection that causes significant morbidity and mortality worldwide, with influenza A being the subtype most responsible for pandemics due to its high susceptibility to antigenic variation (<xref rid="B1" ref-type="bibr">1</xref><xref rid="B2" ref-type="bibr">&#8211;</xref><xref rid="B3" ref-type="bibr">3</xref>). Severe influenza primarily affects high-risk populations, including the elderly, young children, obese individuals, pregnant women, and those with chronic underlying diseases. However, it can also impact individuals in the general population (<xref rid="B4" ref-type="bibr">4</xref><xref rid="B5" ref-type="bibr">&#8211;</xref><xref rid="B7" ref-type="bibr">7</xref>). RNA polymerase is an enzyme that catalyzes the chemical reactions that synthesize RNA from a DNA template; this enzyme plays a crucial role in regulating the life cycle of the influenza A virus. Owing to the highly conserved nature of the gene sequences encoding its subunits, RNA polymerase has become a key target for modern antiviral therapies (<xref rid="B8" ref-type="bibr">8</xref><xref rid="B9" ref-type="bibr">&#8211;</xref><xref rid="B10" ref-type="bibr">10</xref>). The influenza virus RNA polymerase complex consists of three subunits: polymerase acidic protein (PA), polymerase basic protein 1 (PB1), and PBP2 (<xref rid="B10" ref-type="bibr">10</xref><xref rid="B11" ref-type="bibr">&#8211;</xref><xref rid="B12" ref-type="bibr">12</xref>). The polymerase basic protein 2 (PB2) subunit, one of the most common subunits of RNA polymerase, plays a critical role in binding to the 5&#8242;-cap domain of host pre-mRNAs, which is essential for viral mRNA translation (<xref rid="B13" ref-type="bibr">13</xref><xref rid="B14" ref-type="bibr">&#8211;</xref><xref rid="B16" ref-type="bibr">16</xref>). Onradivir (ZSP1273), developed by Guangdong Raynovent Biotech Co., Ltd., is an inhibitor of the PB2 subunit of the influenza virus RNA polymerase (<xref rid="B17" ref-type="bibr">17</xref>).</p><p>Preclinical studies have shown that onradivir has strong antiviral activity both <italic toggle="yes">in vivo</italic> and <italic toggle="yes">in vitro</italic> (<xref rid="B17" ref-type="bibr">17</xref>). Clinical trial results indicate that onradivir significantly reduces the time to alleviate symptoms in Chinese participants with influenza A (<xref rid="B18" ref-type="bibr">18</xref>). A complete clinical mass balance study revealed that onradivir is primarily present in plasma as the parent drug, with mean cumulative recovery rates of onradivir-related substances in urine and feces of 8.75% and 83.24% of the administered dose, respectively. Less than 1% of the parent drug was recovered in urine, whereas 59.9% was recovered in feces, suggesting that onradivir is predominantly eliminated via nonrenal pathways. The major metabolites identified in plasma, urine, and feces were glucuronide and mono-oxidized metabolites, indicating that onradivir is primarily eliminated through hepatic pathways, including glucuronidation, oxidation, and biliary excretion. Additionally, a pharmacokinetics (PK) clinical trial conducted in Chinese participants with impaired hepatic function revealed that hepatic impairment significantly affected the absorption and elimination of onradivir (<xref rid="B19" ref-type="bibr">19</xref>).</p><p>Given that impaired renal function can affect drug absorption, distribution, metabolism, and transport pathways in the liver and gut, particularly in patients with severe renal impairment, understanding the impact of renal impairment on the PK, tolerability, and safety of onradivir is crucial for informing appropriate dose adjustments (<xref rid="B20" ref-type="bibr">20</xref><xref rid="B21" ref-type="bibr">&#8211;</xref><xref rid="B22" ref-type="bibr">22</xref>). The aim of this study was to provide guidance regarding clinical dosing for patients with renal impairment by evaluating the impact of severe renal impairment on the PK, safety, and tolerability of onradivir in a nonrandomized, parallel, single-dose study.</p></sec><sec sec-type="materials|methods" id="s2"><title>MATERIALS AND METHODS</title><sec id="s2-1"><title>Study design</title><p>This was a phase I, nonrandomized, open-label, parallel, single-dose clinical trial to evaluate the PK, safety, and tolerability of onradivir in participants with normal renal function and severe renal impairment. A total of 16 participants were enrolled and assigned to either the healthy group or the renal impairment group. All participants were admitted to the clinic the day before medication administration and fasted for at least 10 h. On the following morning, all participants received a dose of 600 mg onradivir, administered with 240 mL of warm water. Participants were instructed not to consume any water for 1 h before and 2 h after administration, and food was prohibited until 4 h after administration.</p></sec><sec id="s2-2"><title>Study population</title><p>The study was conducted at the First Affiliated Hospital of Xiamen University and the First Affiliated Hospital of Jinan University in China from December 2023 to April 2024 and received approval from an independent Ethics Committee. Written informed consent was obtained from all participants (the first participant provided informed consent on 21 December 2023). This clinical trial (Clinical Trials Registration: <ext-link ext-link-type="pmc:clinical-trial" xlink:href="NCT06248567">NCT06248567</ext-link>; <ext-link xlink:href="https://clinicaltrials.gov" ext-link-type="uri">https://clinicaltrials.gov</ext-link>) adhered to the principles of the Declaration of Helsinki and Good Clinical Practice.</p><p>Participants aged 18&#8211;65 years, with a body weight of &#8805;50 kg for males and &#8805;40 kg for females, were eligible for this study. Additional criteria included a body mass index (BMI) of 18&#8211;28 kg/m<sup>2</sup>. There were no restrictions regarding ethnicity. Participants with severe renal impairment needed to meet the criteria for chronic kidney disease (CKD), indicated by markers of kidney damage or an estimated glomerular filtration rate (eGFR) &lt;60 mL/min (determined by the CKD-EPI equation [<xref rid="B23" ref-type="bibr">23</xref>]) for more than 3 months and an eGFR of 15&#8211;29 mL/min (inclusive) to qualify as CKD stage IV. Participants with normal renal function were required to have an eGFR &gt;90 mL/min and were matched with those in the severe renal impairment group based on weight (mean &#177; 10 kg), age (mean &#177; 10 years), and sex (&#177;1 participant).</p><p>The primary exclusion criteria included females who were either pregnant or breastfeeding; individuals with uncontrolled or unstable cardiovascular diseases, those with a history of alcohol or drug abuse; and individuals who had used uridine diphosphate-glucuronosyltransferase (UGT) inhibitors or inducers. Additional exclusion criteria for the severe renal impairment group included acute renal failure, a history of kidney transplantation, or the need for dialysis during the study. For the healthy group, exclusion criteria included clinically significant abnormalities in clinical laboratory examinations or any clinically significant disease identified within 12 months prior to screening.</p></sec><sec id="s2-3"><title>PK assessment</title><sec id="s2-3-1"><title>Plasma</title><p>Blood samples (4 mL) were collected in K<sub>2</sub>-EDTA tubes at predose, 0.25 h, 0.5 h, 0.75 h, 1 h, 1.5 h, 2 h, 3 h, 4 h, 6 h, 8 h, 12 h, 16 h, 24 h, 48 h, 72 h, 96 h, and 120 h post-dose. Samples were gently inverted 8&#8211;10 times and then centrifuged at 1,700 &#215; <italic toggle="yes">g</italic> for 10 min at 4&#176;C to obtain clear plasma, which was separated and stored at &#8722;80&#176;C within 1 h after collection.</p><p>The high-performance liquid chromatography-tandem mass spectroscopy (HPLC&#8211;MS/MS) assay was validated according to current guidelines for the analysis of plasma samples, with a concentration range of 4.00&#8211;10,000 ng/mL for total onradivir and 20.0&#8211;10,000 pg/mL for unbound onradivir (<xref rid="B24" ref-type="bibr">24</xref>). Samples were processed using protein precipitation or liquid-liquid extraction prior to HPLC-MS/MS analysis. Onradivir-d4 was used as the stable isotope-labeled internal standard (IS).</p><p>For the total onradivir assay, the mass spectrometer used was an AB Sciex Triple Quad 4500 in multiple reaction monitoring (MRM) mode, with mass transitions m/z 441.2&#8594;289.2 Da (onradivir) and m/z 445.2&#8594;293.0 Da (IS). The LC system was a Shimadzu LC-20ADXR, with an Ultimate XB C18 column (2.1 &#215; 50.0 mm, 5.0 &#181;m, Welch, Maryland, USA). For unbound onradivir assay, the mass spectrometer used was an AB Sciex Triple Quad 6500 in Low Mass MRM mode, with mass transitions m/z 441.2&#8594;289.2 Da (onradivir) and m/z 445.1&#8594;135.1 Da (IS). The LC system was a Shimadzu LC-20ADXR, with an ACE C18 column (2.1 &#215; 50.0 mm, 5.0 &#181;m, ACE, Pennsylvania, USA).</p><p>Quantification was performed by peak area ratios of onradivir vs IS, with calibration curves fitted via weighted linear regression (1/concentration<sup>2</sup>). The lower limit of quantitation (LLOQ) for total onradivir and unbound onradivir was 4.00 ng/mL and 20.00 pg/mL, respectively.</p></sec><sec id="s2-3-2"><title>Urine</title><p>Urine samples were collected at specific time intervals: predose (omitted if the participant did not urinate), 0&#8211;6 h, 6&#8211;12 h, 12&#8211;24 h, 24&#8211;48 h, 48&#8211;72 h, 72&#8211;96 h, and 96&#8211;120 h post-dose. Urine samples were mixed and aliquoted within 1 h after being collected and then stored at &#8722;80&#176;C within 1 h after being aliquoted.</p><p>The assay was validated according to current guidelines for analyzing urine samples in the concentration range 2.00&#8211;1,000 ng/mL, with onradivir-d4 as the stable isotope-labeled IS (<xref rid="B24" ref-type="bibr">24</xref>). Samples were processed using liquid-liquid extraction prior to HPLC&#8211;MS/MS analysis. The mass spectrometer used was an AB Sciex Triple Quad 4500 in MRM mode, with mass transitions <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> 441.2&#8594;289.2 Da (onradivir) and <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> 445.1&#8594;135.1 Da (IS). The LC system was the same as that used for the total onradivir assay in plasma.</p><p>Quantification was performed by peak area ratios of onradivir vs IS, with calibration curves fitted via weighted linear regression (1/concentration<sup>2</sup>). The LLOQ was 2.00 ng/mL.</p></sec></sec><sec id="s2-4"><title>PK analyses</title><p>The PK parameters were calculated via a noncompartmental model with Phoenix WinNonlin version 8.4 (Certara [USA], agented by Shanghai Yuanzi Biotech Co., Ltd., Shanghai, China). Actual sampling times were used for PK calculations, with concentrations below the limit of quantification being replaced with zero before <italic toggle="yes">T</italic><sub>max</sub> (time of maximum observed concentration) and with &#8220;ND&#8221; after <italic toggle="yes">T</italic><sub>max</sub>. The main PK parameters were as follows.</p><p><italic toggle="yes">C</italic><sub>max</sub> and <italic toggle="yes">T</italic><sub>max</sub> were directly obtained from the plasma concentration-time data. The first-order rate constant (&#955;<sub><italic toggle="yes">z</italic></sub>) was estimated by linear regression of time vs log concentration. AUC<sub>0&#8211;<italic toggle="yes">t</italic></sub> was calculated using a linear trapezoidal method. AUC<sub>0&#8211;inf</sub> was calculated as follows: AUC<sub>0&#8211;inf</sub> = AUC<sub>0&#8211;<italic toggle="yes">t</italic></sub> + <italic toggle="yes">C</italic><sub><italic toggle="yes">t</italic></sub>/&#955;<sub><italic toggle="yes">z</italic></sub>, where <italic toggle="yes">C</italic><sub><italic toggle="yes">t</italic></sub> was the last measurable concentration. The terminal elimination half-life (<italic toggle="yes">t</italic><sub>1/2</sub>) was calculated as ln2/&#955;<sub><italic toggle="yes">z</italic></sub>. The total clearance (CL/F) was calculated as dose/AUC<sub>0&#8211;inf</sub>, and the distribution volume (Vz/F) was calculated as CL/&#955;<sub><italic toggle="yes">z</italic></sub>. The percentage of AUC<sub>0&#8211;inf</sub> due to extrapolation from <italic toggle="yes">T</italic><sub>last</sub> (time of last measurable concentration) to infinity (AUC<sub>_%Extrap</sub>) was calculated as 100 &#215; ([AUC<sub>0&#8211;inf</sub> &#8211; AUC<sub>0&#8211;<italic toggle="yes">t</italic></sub>]/AUC<sub>0&#8211;inf</sub>). The amount of onradivir recovered from urine over the 0&#8211;120 h post-dose (Ae<sub>0&#8211;120</sub>), the recovery rate of onradivir in urine over the same period (Fe<sub>0&#8211;120</sub>), and the renal clearance (CL<sub>r</sub>) were calculated as follows: Ae<sub>0&#8211;120</sub> = <inline-formula id="ui1"><alternatives><inline-graphic xlink:href="aac.00462-25.im001.jpg"/><mml:math id="u1" display="inline" overflow="scroll"><mml:mrow><mml:msubsup><mml:mo stretchy="false">&#8721;</mml:mo><mml:mrow><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>n</mml:mi></mml:mrow></mml:msubsup><mml:mrow><mml:mi mathvariant="normal"/></mml:mrow></mml:mrow></mml:math></alternatives></inline-formula> C<sub>urine, <italic toggle="yes">i</italic></sub> &#215; V<sub>urine, <italic toggle="yes">i</italic></sub> (<italic toggle="yes">i</italic> = 1 represents the first collection interval, <italic toggle="yes">n</italic> is the total number of collection intervals); Fe<sub>0&#8211;120</sub> = Ae<sub>0&#8211;120</sub>/dose &#215; 100%; CL<sub>r</sub>/F = Ae<sub>0&#8211;120</sub>/AUC<sub>0&#8211;<italic toggle="yes">t</italic></sub>. The fraction of unbound drug (fu) was calculated as follows: fu<sub><italic toggle="yes">t</italic></sub> (%) = <italic toggle="yes">C</italic><sub><italic toggle="yes">t</italic></sub> (concentration of unbound onradivir)/<italic toggle="yes">C</italic><sub><italic toggle="yes">t</italic></sub> (concentration of total onradivir) &#215; 100, and the plasma protein binding (PPB) ratio was calculated as follows: PPB<sub><italic toggle="yes">t</italic></sub> (%) = 100 fu<sub><italic toggle="yes">t</italic></sub> (%), where <italic toggle="yes">t</italic> represents <italic toggle="yes">T</italic><sub>max</sub> and <italic toggle="yes">T</italic><sub>min</sub> (24 h after administration).</p><p>In accordance with ICH guidelines (<xref rid="B25" ref-type="bibr">25</xref>), participants with an extrapolated AUC<sub>0&#8211;inf</sub> percentage exceeding 20% were identified, and the corresponding AUC<sub>0&#8211;inf</sub>, <italic toggle="yes">t</italic><sub>1/2</sub>, CL/F, Vz/F, and &#955;<sub><italic toggle="yes">z</italic></sub> values were excluded from the statistical analysis. The potential impact of this exclusion on the bioequivalence evaluation (variance analysis) was assessed. In addition, participants meeting the following criteria were excluded from the PK parameter analysis: (i) serious violation of the clinical trial protocol that affects PK results or prevents PK estimation; (ii) a predose plasma concentration greater than 5% of <italic toggle="yes">C</italic><sub>max</sub>; (iii) a <italic toggle="yes">C</italic><sub>max</sub> for the first sample and early samples (5&#8211;15 minutes post-dose) was not collected; (iv) vomiting within twice the median <italic toggle="yes">T</italic><sub>max</sub> in the same group; and (v) the use of concomitant medication during the trial that impacts PK parameters.</p></sec><sec id="s2-5"><title>Safety assessment</title><p>Changes in physical examination, vital sign, clinical laboratory examination (hematology, urinalysis, blood chemistry, and coagulation profile), and 12-lead electrocardiogram (ECG) signal data, along with other examination data, were surveilled. Adverse events (AEs), including severity, occurrence time, end time, duration, treatment measures, and outcomes, were also recorded.</p></sec><sec id="s2-6"><title>Statistical analysis</title><p>The sample size in this study was not determined based on statistical hypothesis testing.</p><p>Statistical analysis was conducted using SAS version 9.4 (SAS Institute Inc. [USA], agented by Beijing Jingqiang Technology Development Co., Ltd., Beijing, China). For quantitative variables, descriptive statistics included the number of participants, mean, SD, minimum, maximum, and median. For categorical variables, descriptive statistics included the frequencies and percentages.</p><p>Primary PK parameters <italic toggle="yes">C</italic><sub>max</sub> and AUC were compared between participants with renal impairment and those with normal renal function. Analysis of variance was performed on the logarithmically transformed <italic toggle="yes">C</italic><sub>max</sub> and AUC values to estimate the geometric mean ratios (GMR; renal impairment group/healthy group) and their 90% confidence interval (CI). The Wilcoxon rank-sum test was used to analyze <italic toggle="yes">T</italic><sub>max</sub>, while other PK parameters were assessed using the Student&#8217;s <italic toggle="yes">t</italic>-test.</p><p>AEs were coded via the Medical Dictionary for Regulatory Activities (MedDRA version 26.0 or above) and summarized descriptively. Fisher&#8217;s exact test (two-sided) was used for the statistical analysis of adverse event incidence.</p></sec></sec><sec sec-type="results" id="s3"><title>RESULTS</title><sec id="s3-1"><title>Population</title><p>A total of 16 participants (<italic toggle="yes">n</italic> = eight per group) were enrolled in this trial, all of whom were administered as planned and completed the trial. Weight, height, BMI range, and sex ratio were comparable between the renal impairment group and the healthy control group. Although the mean age of the renal impairment group was higher than that of the healthy group, the difference was within acceptable criteria. The mean eGFR was 21.63 (16.00&#8211;29.00) mL/min in the renal impairment group and 106.13 (97.00&#8211;118.00) mL/min in the healthy group (Supplementary, <xref rid="SuF1" ref-type="supplementary-material">Table S1</xref>).</p></sec><sec id="s3-2"><title>Concentration assay</title><p>The bioanalytical assays for total onradivir in plasma, unbound onradivir in plasma, and onradivir in urine demonstrated high precision and accuracy. The maximum precision (%CV) for calibration standards and quality control samples was 6.4%, 6.6%, and 5.4% for total plasma, unbound plasma, and urinary onradivir, respectively. Mean accuracy deviations ranged from &#8722;4.1% to 3.5% for total plasma onradivir, &#8722;5.0% to 4.0% for unbound plasma onradivir, and &#8722;1.6% to 3.0% for urinary onradivir. Incurred sample reanalysis (ISR) met acceptance criteria, with pass rates of 100%, 88.9%, and 100% for total plasma, unbound plasma, and urinary onradivir assays, respectively. Several biological samples required reanalysis due to analytical issues. In the renal impairment group, one participant (A004 at 1.5 h) had a repeated total onradivir assay because the initial concentration exceeded the upper limit of quantification (ULOQ). Another participant (A005 at 24 h) underwent a repeated unbound onradivir assay due to a significant discrepancy between the initial result and the ISR value. In the healthy group, three participants (B004 at 12 h, B006 at 6 h, and B007 at 6 h) required repeated urine sample assays due to concentrations exceeding the ULOQ. These results confirm the bioanalytical method&#8217;s robust reproducibility and reliability.</p></sec><sec id="s3-3"><title>PK analysis</title><p>The mean plasma concentration-time profiles of onradivir were similar across the two groups (<xref rid="F1" ref-type="fig">Fig. 1</xref>).</p><fig position="float" fig-type="figure" id="F1" orientation="portrait"><label>Fig 1</label><caption><p>Onradivir arithmetic mean (SD) plasma concentration-time profiles on a linear scale (<bold>A</bold>) and arithmetic mean plasma concentration-time profiles on a semilog scale (<bold>B</bold>) after a single oral dose of 600 mg of onradivir to participants with renal impairment and normal renal function (<italic toggle="yes">n</italic> = 8 per group); the inset in panel A is for 0&#8211;12 h.</p></caption><graphic position="float" orientation="portrait" xlink:href="aac.00462-25.f001.jpg"><alt-text>Two-part line graph depicting plasma concentration over time for healthy and renal impairment groups using linear and logarithmic scales, both illustrating higher peak and faster decline in renal impairment compared to healthy across 120 hours.</alt-text></graphic></fig><p>Following a single dose of onradivir, the median <italic toggle="yes">T</italic><sub>max</sub> was 1.48 h in the renal impairment group and 0.86 h in the healthy group, with comparable <italic toggle="yes">C</italic><sub>max</sub> values in both groups (6,848.10 ng&#183;mL<sup>&#8722;1</sup> vs 6,756.90 ng&#183;mL<sup>&#8722;1</sup>, <italic toggle="yes">P</italic> &gt; 0.05; <xref rid="T1" ref-type="table">Table 1</xref>). Compared with the healthy group, the geometric mean AUC<sub>0&#8211;<italic toggle="yes">t</italic></sub> and AUC<sub>0&#8211;inf</sub> values in the renal impairment group were reduced by 23.69% and 23.44% (<xref rid="T1" ref-type="table">Table 1</xref>), respectively; however, these differences were not statistically significant (both <italic toggle="yes">P</italic> &gt; 0.05). The renal impairment group showed a higher geometric mean elimination rate (39,178.92 mL/h vs 29,996.04 mL/h, <italic toggle="yes">P</italic> &gt; 0.05) and shorter <italic toggle="yes">t</italic><sub>1/2</sub> (12.62 h vs 24.31 h, <italic toggle="yes">P</italic> &lt; 0.05) compared to the healthy control group. However, renal clearance was significantly lower in the renal impairment group (3.08 mL/h vs 33.03 mL/h, <italic toggle="yes">P</italic> &lt; 0.05).</p><table-wrap position="float" id="T1" orientation="portrait"><label>TABLE 1</label><caption><p>Summary of PK parameters in the renal impairment group and healthy group<xref rid="T1_FN3" ref-type="table-fn"><sup><italic toggle="yes">c</italic></sup></xref></p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><thead><tr><th align="left" valign="top" colspan="1" rowspan="1">PK parameter</th><th align="left" valign="top" colspan="1" rowspan="1">Renal impairment group (<italic toggle="yes">N</italic> = 8)</th><th align="left" valign="top" colspan="1" rowspan="1">Healthy group (<italic toggle="yes">N</italic> = 8)</th><th align="left" valign="top" colspan="1" rowspan="1">GMR (%)</th><th align="left" valign="top" colspan="1" rowspan="1">90% CI (%)</th><th align="left" valign="top" colspan="1" rowspan="1">CV (%)</th><th align="left" valign="top" colspan="1" rowspan="1"><italic toggle="yes">P</italic> value</th></tr></thead><tbody><tr><td align="left" valign="top" colspan="1" rowspan="1"><italic toggle="yes">T</italic><sub>max</sub> (h)</td><td align="left" valign="top" colspan="1" rowspan="1">1.48 (0.75, 2.95)</td><td align="left" valign="top" colspan="1" rowspan="1">0.86 (0.48, 2)</td><td align="left" valign="top" colspan="1" rowspan="1">/<xref rid="T1_FN4" ref-type="table-fn"><sup><italic toggle="yes">d</italic></sup></xref></td><td align="left" valign="top" colspan="1" rowspan="1">/</td><td align="left" valign="top" colspan="1" rowspan="1">/</td><td align="left" valign="top" colspan="1" rowspan="1">0.225</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1"><italic toggle="yes">C</italic><sub>max</sub> (ng&#183;mL<sup>&#8722;1</sup>)</td><td align="left" valign="top" colspan="1" rowspan="1">6,848.10 (77.78)</td><td align="left" valign="top" colspan="1" rowspan="1">6,756.90 (28.34)</td><td align="left" valign="top" colspan="1" rowspan="1">101.35</td><td align="left" valign="top" colspan="1" rowspan="1">(63.85,160.86)</td><td align="left" valign="top" colspan="1" rowspan="1">56.28</td><td align="left" valign="top" colspan="1" rowspan="1">0.960</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">AUC<sub>0&#8211;<italic toggle="yes">t</italic></sub> (ng&#183;h&#183;mL<sup>&#8722;1</sup>)</td><td align="left" valign="top" colspan="1" rowspan="1">15,071.73 (55.23)</td><td align="left" valign="top" colspan="1" rowspan="1">19,751.65 (31.66)</td><td align="left" valign="top" colspan="1" rowspan="1">76.31</td><td align="left" valign="top" colspan="1" rowspan="1">(52.47,110.97)</td><td align="left" valign="top" colspan="1" rowspan="1">44.53</td><td align="left" valign="top" colspan="1" rowspan="1">0.224</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">AUC<sub>0&#8211;inf</sub> (ng&#183;h&#183;mL<sup>&#8722;1</sup>)</td><td align="left" valign="top" colspan="1" rowspan="1">15,314.36 (54.95)</td><td align="left" valign="top" colspan="1" rowspan="1">20,002.64 (35.27)<xref rid="T1_FN1" ref-type="table-fn"><sup><italic toggle="yes">a</italic></sup></xref></td><td align="left" valign="top" colspan="1" rowspan="1">76.56</td><td align="left" valign="top" colspan="1" rowspan="1">(51.02,114.90)</td><td align="left" valign="top" colspan="1" rowspan="1">46.56</td><td align="left" valign="top" colspan="1" rowspan="1">0.265</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">AUC<sub>0&#8211;inf</sub> (ng&#183;h/mL)</td><td align="left" valign="top" colspan="1" rowspan="1">15,314.36 (54.95)</td><td align="left" valign="top" colspan="1" rowspan="1">20,881.67(34.96)<xref rid="T1_FN2" ref-type="table-fn"><sup><italic toggle="yes">b</italic></sup></xref></td><td align="left" valign="top" colspan="1" rowspan="1">73.34</td><td align="left" valign="top" colspan="1" rowspan="1">(49.98,107.61)</td><td align="left" valign="top" colspan="1" rowspan="1">45.69</td><td align="left" valign="top" colspan="1" rowspan="1">0.176</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">&#955;<sub><italic toggle="yes">z</italic></sub> (h<sup>&#8722;1</sup>)</td><td align="left" valign="top" colspan="1" rowspan="1">0.05 (50.03)</td><td align="left" valign="top" colspan="1" rowspan="1">0.03 (44.78)</td><td align="left" valign="top" colspan="1" rowspan="1">/</td><td align="left" valign="top" colspan="1" rowspan="1">/</td><td align="left" valign="top" colspan="1" rowspan="1">/</td><td align="left" valign="top" colspan="1" rowspan="1">0.008</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1"><italic toggle="yes">t</italic><sub>1/2</sub> (h)</td><td align="left" valign="top" colspan="1" rowspan="1">12.62 (50.03)</td><td align="left" valign="top" colspan="1" rowspan="1">24.31 (44.78)</td><td align="left" valign="top" colspan="1" rowspan="1">/</td><td align="left" valign="top" colspan="1" rowspan="1">/</td><td align="left" valign="top" colspan="1" rowspan="1">/</td><td align="left" valign="top" colspan="1" rowspan="1">0.008</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1"><italic toggle="yes">V</italic><sub><italic toggle="yes">z</italic></sub>/<italic toggle="yes">F</italic> (mL)</td><td align="left" valign="top" colspan="1" rowspan="1">713,087.32 (95.17)</td><td align="left" valign="top" colspan="1" rowspan="1">1,052,144.9 (48.87)</td><td align="left" valign="top" colspan="1" rowspan="1">/</td><td align="left" valign="top" colspan="1" rowspan="1">/</td><td align="left" valign="top" colspan="1" rowspan="1">/</td><td align="left" valign="top" colspan="1" rowspan="1">0.173</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">CL/F (mL&#183;h<sup>&#8722;1</sup>)</td><td align="left" valign="top" colspan="1" rowspan="1">39,178.92 (54.95)</td><td align="left" valign="top" colspan="1" rowspan="1">29,996.04 (35.27)</td><td align="left" valign="top" colspan="1" rowspan="1">/</td><td align="left" valign="top" colspan="1" rowspan="1">/</td><td align="left" valign="top" colspan="1" rowspan="1">/</td><td align="left" valign="top" colspan="1" rowspan="1">0.176</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">AUC<sub>_%Extrap</sub> (%)</td><td align="left" valign="top" colspan="1" rowspan="1">1.11 (122.12)</td><td align="left" valign="top" colspan="1" rowspan="1">1.85 (76.86)</td><td align="left" valign="top" colspan="1" rowspan="1">/</td><td align="left" valign="top" colspan="1" rowspan="1">/</td><td align="left" valign="top" colspan="1" rowspan="1">/</td><td align="left" valign="top" colspan="1" rowspan="1">0.131</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">Ae<sub>0&#8211;120 h</sub> (ng)</td><td align="left" valign="top" colspan="1" rowspan="1">46,441.44 (303.73)</td><td align="left" valign="top" colspan="1" rowspan="1">652,356.02 (88.76)</td><td align="left" valign="top" colspan="1" rowspan="1">/</td><td align="left" valign="top" colspan="1" rowspan="1">/</td><td align="left" valign="top" colspan="1" rowspan="1">/</td><td align="left" valign="top" colspan="1" rowspan="1">0.001</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">Fe<sub>0&#8211;120 h</sub> (%)</td><td align="left" valign="top" colspan="1" rowspan="1">0.01 (303.73)</td><td align="left" valign="top" colspan="1" rowspan="1">0.11 (88.76)</td><td align="left" valign="top" colspan="1" rowspan="1">/</td><td align="left" valign="top" colspan="1" rowspan="1">/</td><td align="left" valign="top" colspan="1" rowspan="1">/</td><td align="left" valign="top" colspan="1" rowspan="1">0.001</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">CL<sub>r</sub>/F (mL&#183;h<sup>&#8722;1</sup>)</td><td align="left" valign="top" colspan="1" rowspan="1">3.08 (151.63)</td><td align="left" valign="top" colspan="1" rowspan="1">33.03 (92.98)</td><td align="left" valign="top" colspan="1" rowspan="1">/</td><td align="left" valign="top" colspan="1" rowspan="1">/</td><td align="left" valign="top" colspan="1" rowspan="1">/</td><td align="left" valign="top" colspan="1" rowspan="1">0.000</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">fu<sub><italic toggle="yes">T</italic>max</sub> (%)</td><td align="left" valign="top" colspan="1" rowspan="1">0.024 (32.303)</td><td align="left" valign="top" colspan="1" rowspan="1">0.013 (15.473)</td><td align="left" valign="top" colspan="1" rowspan="1">/</td><td align="left" valign="top" colspan="1" rowspan="1">/</td><td align="left" valign="top" colspan="1" rowspan="1">/</td><td align="left" valign="top" colspan="1" rowspan="1">0.000</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">PPB<sub><italic toggle="yes">T</italic>max</sub> (%)</td><td align="left" valign="top" colspan="1" rowspan="1">99.975 (0.008)</td><td align="left" valign="top" colspan="1" rowspan="1">99.987 (0.002)</td><td align="left" valign="top" colspan="1" rowspan="1">/</td><td align="left" valign="top" colspan="1" rowspan="1">/</td><td align="left" valign="top" colspan="1" rowspan="1">/</td><td align="left" valign="top" colspan="1" rowspan="1">0.001</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">fu<sub><italic toggle="yes">T</italic>min</sub> (%)</td><td align="left" valign="top" colspan="1" rowspan="1">0.028 (46.317)</td><td align="left" valign="top" colspan="1" rowspan="1">0.013 (21.348)</td><td align="left" valign="top" colspan="1" rowspan="1">/</td><td align="left" valign="top" colspan="1" rowspan="1">/</td><td align="left" valign="top" colspan="1" rowspan="1">/</td><td align="left" valign="top" colspan="1" rowspan="1">0.012</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">PPB<sub><italic toggle="yes">T</italic>min</sub> (%)</td><td align="left" valign="top" colspan="1" rowspan="1">99.969 (0.013)</td><td align="left" valign="top" colspan="1" rowspan="1">99.987 (0.002)</td><td align="left" valign="top" colspan="1" rowspan="1">/</td><td align="left" valign="top" colspan="1" rowspan="1">/</td><td align="left" valign="top" colspan="1" rowspan="1">/</td><td align="left" valign="top" colspan="1" rowspan="1">0.032</td></tr></tbody></table><table-wrap-foot><fn id="T1_FN1"><label>
<sup>
<italic toggle="yes">a</italic>
</sup>
</label><p>The AUC_<sub>% Extrap</sub> of B007 (healthy group) was greater than 20%, and the AUC<sub>0&#8211;inf</sub> was not included in the analysis.</p></fn><fn id="T1_FN2"><label>
<sup>
<italic toggle="yes">b</italic>
</sup>
</label><p>Sensitivity analysis, the AUC<sub>0&#8211;inf</sub> of B007 was included.</p></fn><fn id="T1_FN3"><label>
<sup>
<italic toggle="yes">c</italic>
</sup>
</label><p>The PK parameters are presented as geometric means (coefficients of variation between participants), except for <italic toggle="yes">T</italic><sub>max</sub>, which is presented as median (min, max). GMR: geometric mean ratio (renal impairment group/healthy group); CI: confidence interval; CV: coefficient of variation of renal impairment group and healthy group.</p></fn><fn id="T1_FN4"><label>
<sup>
<italic toggle="yes">d</italic>
</sup>
</label><p>/, not applicable.</p></fn></table-wrap-foot></table-wrap><p>In this study, the free fraction of onradivir was measured at <italic toggle="yes">T</italic><sub>max</sub> and <italic toggle="yes">T</italic><sub>min</sub> due to its high binding affinity to plasma proteins. Both groups presented a PPB ratio above 99.9% across all participants, whereas the renal impairment group presented a greater fu. The free fraction of PK parameters (<italic toggle="yes">C</italic><sub>max</sub> and AUC<sub>0-inf</sub>) was estimated with fu (<xref rid="F2" ref-type="fig">Fig. 2</xref>). Although differences were observed in the means and medians between the two groups, the renal impairment group presented greater variability, with most exposure (AUC<sub>0&#8211;inf</sub>) levels falling within the range of those of the healthy group.</p><fig position="float" fig-type="figure" id="F2" orientation="portrait"><label>Fig 2</label><caption><p>Free fraction exposure (fuC<sub>max</sub> and fuAUC<sub>0&#8211;inf</sub>) of onradivir in the renal impairment group and healthy group. fuC<sub>max</sub> = fuT<sub>max</sub> &#215; <italic toggle="yes">C</italic><sub>max</sub>, fuAUC<sub>0&#8211;inf</sub> = average (fu<sub>Tmax</sub>, fu<sub>T24h</sub>) &#215; AUC<sub>0&#8211;inf</sub>. The solid circles represent the geometric mean, whereas the hollow circles represent individual observations. In each box, the bottom, middle, and top lines correspond to the 25th, 50th, and 75th percentiles, respectively. The lower and upper whiskers represent the minimum and maximum observations within 1.5 times the interquartile range from the box edges.</p></caption><graphic position="float" orientation="portrait" xlink:href="aac.00462-25.f002.jpg"><alt-text>Box plots depicting fuCmax and fuAUC from zero to infinity for healthy and renal impairment groups. Both values are higher in renal impairment with greater variability compared to lower and narrower range in healthy group.</alt-text></graphic></fig><p>In summary, there was no significant difference in exposure (<italic toggle="yes">C</italic><sub>max</sub> and AUC) between healthy participants and those with severe renal impairment.</p></sec><sec id="s3-4"><title>Safety and tolerability</title><p>Nine participants (56.3%) reported a total of 14 treatment-emergent adverse events (TEAEs), including three participants (37.5%, five TEAEs) in the renal impairment group and six participants (75.0%, nine TEAEs) in the healthy group (<xref rid="T2" ref-type="table">Table 2</xref>). The incidence of TEAEs between the two groups was not significantly different (<italic toggle="yes">P</italic> &gt; 0.05). The TEAEs included cardiac disorders, investigations, gastrointestinal disorders, metabolism and nutrition disorders, and infections and infestations. The severity of the TEAEs ranged from grades 1 to 2, with one case of grade 2 hyperkalemia requiring drug treatment in the renal impairment group. The TEAEs were short in duration (3&#8211;8 days) and either recovered or improved before the end of the study. No participants withdrew from the study because of TEAEs.</p><table-wrap position="float" id="T2" orientation="portrait"><label>TABLE 2</label><caption><p>Incidence of TEAEs by system organ class and preferred term<xref rid="T2_FN1" ref-type="table-fn"><sup><italic toggle="yes">a</italic></sup></xref></p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><thead><tr><th align="left" valign="top" rowspan="2" colspan="1">System organ class preferred term</th><th align="center" valign="top" colspan="2" rowspan="1">Renal impairment group<break/>(<italic toggle="yes">N</italic> = 8)</th><th align="center" valign="top" colspan="2" rowspan="1">Healthy group<break/>(<italic toggle="yes">N</italic> = 8)</th><th align="left" valign="top" rowspan="2" colspan="1"><italic toggle="yes">P</italic> value<break/>(two side)</th></tr><tr><th align="left" valign="top" colspan="1" rowspan="1"><italic toggle="yes">N</italic> (%)</th><th align="left" valign="top" colspan="1" rowspan="1">
<italic toggle="yes">E</italic>
</th><th align="left" valign="top" colspan="1" rowspan="1"><italic toggle="yes">N</italic> (%)</th><th align="left" valign="top" colspan="1" rowspan="1">
<italic toggle="yes">E</italic>
</th></tr></thead><tbody><tr><td align="left" valign="top" colspan="1" rowspan="1">Total</td><td align="left" valign="top" colspan="1" rowspan="1">3 (37.5)</td><td align="left" valign="top" colspan="1" rowspan="1">5</td><td align="left" valign="top" colspan="1" rowspan="1">6 (75.0)</td><td align="left" valign="top" colspan="1" rowspan="1">9</td><td align="left" valign="top" colspan="1" rowspan="1">0.315</td></tr><tr><td align="left" valign="top" style="background:#E7E6E6" colspan="1" rowspan="1">Cardiac disorders</td><td align="left" valign="top" style="background:#E7E6E6" colspan="1" rowspan="1">2 (25.0)</td><td align="left" valign="top" style="background:#E7E6E6" colspan="1" rowspan="1">2</td><td align="left" valign="top" style="background:#E7E6E6" colspan="1" rowspan="1">5 (62.5)</td><td align="left" valign="top" style="background:#E7E6E6" colspan="1" rowspan="1">5</td><td align="left" valign="top" style="background:#E7E6E6" colspan="1" rowspan="1">0.315</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">Sinus bradycardia</td><td align="left" valign="top" colspan="1" rowspan="1">1 (12.5)</td><td align="left" valign="top" colspan="1" rowspan="1">1</td><td align="left" valign="top" colspan="1" rowspan="1">5 (62.5)</td><td align="left" valign="top" colspan="1" rowspan="1">5</td><td align="left" valign="top" colspan="1" rowspan="1">/<xref rid="T2_FN2" ref-type="table-fn"><sup><italic toggle="yes">b</italic></sup></xref></td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">Atrioventricular block first degree</td><td align="left" valign="top" colspan="1" rowspan="1">1 (12.5)</td><td align="left" valign="top" colspan="1" rowspan="1">1</td><td align="left" valign="top" colspan="1" rowspan="1">0 (0)</td><td align="left" valign="top" colspan="1" rowspan="1">0</td><td align="left" valign="top" colspan="1" rowspan="1">/</td></tr><tr><td align="left" valign="top" style="background:#E7E6E6" colspan="1" rowspan="1">Investigations</td><td align="left" valign="top" style="background:#E7E6E6" colspan="1" rowspan="1">0 (0)</td><td align="left" valign="top" style="background:#E7E6E6" colspan="1" rowspan="1">0</td><td align="left" valign="top" style="background:#E7E6E6" colspan="1" rowspan="1">3 (37.5)</td><td align="left" valign="top" style="background:#E7E6E6" colspan="1" rowspan="1">3</td><td align="left" valign="top" style="background:#E7E6E6" colspan="1" rowspan="1">0.200</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">Blood triglycerides increased</td><td align="left" valign="top" colspan="1" rowspan="1">0 (0)</td><td align="left" valign="top" colspan="1" rowspan="1">0</td><td align="left" valign="top" colspan="1" rowspan="1">1 (12.5)</td><td align="left" valign="top" colspan="1" rowspan="1">1</td><td align="left" valign="top" colspan="1" rowspan="1">/</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">Blood creatinine increased</td><td align="left" valign="top" colspan="1" rowspan="1">0 (0)</td><td align="left" valign="top" colspan="1" rowspan="1">0</td><td align="left" valign="top" colspan="1" rowspan="1">1 (12.5)</td><td align="left" valign="top" colspan="1" rowspan="1">1</td><td align="left" valign="top" colspan="1" rowspan="1">/</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">Blood uric acid increased</td><td align="left" valign="top" colspan="1" rowspan="1">0 (0)</td><td align="left" valign="top" colspan="1" rowspan="1">0</td><td align="left" valign="top" colspan="1" rowspan="1">1 (12.5)</td><td align="left" valign="top" colspan="1" rowspan="1">1</td><td align="left" valign="top" colspan="1" rowspan="1">/</td></tr><tr><td align="left" valign="top" style="background:#E7E6E6" colspan="1" rowspan="1">Gastrointestinal disorders</td><td align="left" valign="top" style="background:#E7E6E6" colspan="1" rowspan="1">1 (12.5)</td><td align="left" valign="top" style="background:#E7E6E6" colspan="1" rowspan="1">1</td><td align="left" valign="top" style="background:#E7E6E6" colspan="1" rowspan="1">1 (12.5)</td><td align="left" valign="top" style="background:#E7E6E6" colspan="1" rowspan="1">1</td><td align="left" valign="top" style="background:#E7E6E6" colspan="1" rowspan="1">1.000</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">Abdominal pain</td><td align="left" valign="top" colspan="1" rowspan="1">0 (0)</td><td align="left" valign="top" colspan="1" rowspan="1">0</td><td align="left" valign="top" colspan="1" rowspan="1">1 (12.5)</td><td align="left" valign="top" colspan="1" rowspan="1">1</td><td align="left" valign="top" colspan="1" rowspan="1">/</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">Diarrhea</td><td align="left" valign="top" colspan="1" rowspan="1">1 (12.5)</td><td align="left" valign="top" colspan="1" rowspan="1">1</td><td align="left" valign="top" colspan="1" rowspan="1">0 (0)</td><td align="left" valign="top" colspan="1" rowspan="1">0</td><td align="left" valign="top" colspan="1" rowspan="1">/</td></tr><tr><td align="left" valign="top" style="background:#E7E6E6" colspan="1" rowspan="1">Metabolism and nutrition disorders</td><td align="left" valign="top" style="background:#E7E6E6" colspan="1" rowspan="1">1 (12.5)</td><td align="left" valign="top" style="background:#E7E6E6" colspan="1" rowspan="1">1</td><td align="left" valign="top" style="background:#E7E6E6" colspan="1" rowspan="1">0 (0)</td><td align="left" valign="top" style="background:#E7E6E6" colspan="1" rowspan="1">0</td><td align="left" valign="top" style="background:#E7E6E6" colspan="1" rowspan="1">1.000</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">Hyperkalemia</td><td align="left" valign="top" colspan="1" rowspan="1">1 (12.5)</td><td align="left" valign="top" colspan="1" rowspan="1">1</td><td align="left" valign="top" colspan="1" rowspan="1">0 (0)</td><td align="left" valign="top" colspan="1" rowspan="1">0</td><td align="left" valign="top" colspan="1" rowspan="1">/</td></tr><tr><td align="left" valign="top" style="background:#E7E6E6" colspan="1" rowspan="1">Infections and infestations</td><td align="left" valign="top" style="background:#E7E6E6" colspan="1" rowspan="1">1 (12.5)</td><td align="left" valign="top" style="background:#E7E6E6" colspan="1" rowspan="1">1</td><td align="left" valign="top" style="background:#E7E6E6" colspan="1" rowspan="1">0 (0)</td><td align="left" valign="top" style="background:#E7E6E6" colspan="1" rowspan="1">0</td><td align="left" valign="top" style="background:#E7E6E6" colspan="1" rowspan="1">1.000</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">Bronchitis</td><td align="left" valign="top" colspan="1" rowspan="1">1 (12.5)</td><td align="left" valign="top" colspan="1" rowspan="1">1</td><td align="left" valign="top" colspan="1" rowspan="1">0 (0)</td><td align="left" valign="top" colspan="1" rowspan="1">0</td><td align="left" valign="top" colspan="1" rowspan="1">/</td></tr></tbody></table><table-wrap-foot><fn id="T2_FN1"><label>
<sup>
<italic toggle="yes">a</italic>
</sup>
</label><p><italic toggle="yes">N</italic>, number of participants; <italic toggle="yes">E</italic>, number of AEs.</p></fn><fn id="T2_FN2"><label>
<sup>
<italic toggle="yes">b</italic>
</sup>
</label><p>/, not applicable.</p></fn></table-wrap-foot></table-wrap><p>In conclusion, a single dose of 600 mg onradivir was well-tolerated and safe in both healthy participants and those with severe renal impairment.</p></sec></sec><sec sec-type="discussion" id="s4"><title>DISCUSSION</title><p>Onradivir, an RNA polymerase basic protein 2 inhibitor for influenza A, is primarily metabolized by UGT and eliminated via non-renal pathways, with &lt;1% recovered in urine and 59.9% in feces. As renal impairment may alter drug PK, a phase I study assessed the PK, tolerability, and safety of a single onradivir dose in patients with severe renal impairment. The results indicated that no dose adjustment is necessary for patients with mild-to-severe renal impairment taking onradivir.</p><p>In the present study, eight participants with severe renal impairment and eight participants with normal renal function were enrolled and matched across age, sex, and weight. The safety and PK profiles of the healthy group were consistent with the findings from the phase I clinical trial (<xref rid="B26" ref-type="bibr">26</xref>). After a single oral dose of onradivir, good tolerability and safety were demonstrated for all participants.</p><p>The results indicated that the median <italic toggle="yes">T</italic><sub>max</sub> was numerically longer in the severe renal impairment group compared to the healthy group (1.48 h vs 0.86 h), suggesting a potential delay in absorption; however, this difference was not statistically significant and did not affect <italic toggle="yes">C</italic><sub>max</sub>. However, severe renal impairment reduced onradivir exposure, with the geometric means of AUC<sub>0&#8211;<italic toggle="yes">t</italic></sub> and AUC<sub>0&#8211;inf</sub> decreasing by 23.69% and 23.44%, respectively, likely due to an increased elimination rate (<italic toggle="yes">t</italic><sub>1/2</sub>: 12.62 h vs 24.31 h), although these differences in AUC<sub>0&#8211;t</sub> and AUC<sub>0&#8211;inf</sub> were not statistically significant. Despite the increased elimination rate, cumulative urinary excretion was lower in the renal impairment group (Fe<sub>0&#8211;120 h</sub>: 0.01% vs 0.11%), suggesting that the reduced exposure could result from increased hepatic rather than renal clearance. Additionally, preclinical studies have demonstrated that onradivir exhibits a high PPB ratio. In this study, the free fraction of onradivir was measured at both peak and trough concentrations, and the results showed a PPB ratio exceeding 99.9% in all participants, although intergroup differences in fu were observed. While there were differences in the geomean and median values of fuAUC<sub>0&#8211;inf</sub> and fuC<sub>max</sub> between the groups (<xref rid="F2" ref-type="fig">Fig. 2</xref>), the severe renal impairment group presented high interindividual variability, with most unbound exposure levels remaining within the range observed in the healthy group. Given the small sample size and the extremely low fu of onradivir (&lt;0.1%), the observed differences are unlikely to have clinical significance.</p><p>A total of nine participants experienced TEAEs, including three in the renal impairment group and six in the healthy group. Most TEAEs were isolated occurrences of mild-to-moderate severity, all of which had resolved or improved by the end of the trial and lasted for a short duration. The incidence of TEAE was notably higher in the healthy group compared to the renal impairment group, which may be related to the reduced drug exposure in the latter. However, there was no statistically significant difference in the incidence of TEAE between the two groups. Given the small sample size of the present study, and considering that the incidence of TEAE in the healthy group was 12.5% (1/8) in a previously completed hepatic impairment PK study (<xref rid="B19" ref-type="bibr">19</xref>), the observed difference may be biased and lacks clinical significance.</p><p>In summary, compared to the healthy group, the renal impairment group exhibited a reduced geometric mean total exposure to onradivir, whereas the geometric mean unbound exposure was elevated. A comprehensive population exposure-response analysis (under submission) revealed no significant relationship between onradivir exposure (<italic toggle="yes">C</italic><sub>max</sub>, AUC, or <italic toggle="yes">C</italic><sub>min</sub>) and the primary efficacy endpoint (time to alleviation of symptoms) or secondary endpoints (time to temperature reduction and cessation of viral shedding). However, an association was observed between onradivir exposure (AUC and <italic toggle="yes">C</italic><sub>max</sub>) and the incidence of diarrhea. These findings suggest that severe renal impairment does not have clinically significant effects on the PK of onradivir. According to Food and Drug Administration (FDA) guidance, for drugs like onradivir that are primarily eliminated via nonrenal pathways and intended for use in patients with renal impairment, if no meaningful PK differences are observed in participants with severe renal impairment, further dedicated renal impairment studies are not warranted (<xref rid="B22" ref-type="bibr">22</xref>). Therefore, no dose adjustment is required for patients with mild, moderate, or severe renal impairment.</p><p>A limitation of this study is the small sample size. Additionally, only a single administration of onradivir at one dose was investigated, and as such, the study does not provide insights into the potential effects of renal impairment on drug accumulation following repeated dosing or on dose linearity. This study also focused solely on the safety and PK in participants with severe renal impairment while excluding individuals with end-stage renal failure. Future studies may consider including this patient population and evaluating multiple-dose regimens across a broader dose range.</p><sec id="s4-1"><title>Conclusion</title><p>Severe renal impairment participants showed good tolerance when receiving a single dose of onradivir 600 mg. No dose adjustment is necessary for patients with mild-to-severe renal impairment when taking onradivir.</p></sec></sec></body><back><ack><title>ACKNOWLEDGMENTS</title><p>We thank all participants who voluntarily contributed to this clinical study.</p><p>The study was funded by Guangdong Raynovent Biotech Co., Ltd., Guangzhou, China.</p><p>H.L. and X.Y. contributed to the trial design as well as the analysis and interpretation of the data. Jiyi Huang served as the leading principal investigator, and L.C. served as the principal investigator of this study. X.Y., J.Z., and M.Z. contributed to overseeing data collection, drug administration, and sample management. H.L., Y.L., and X.L. participated in writing the manuscript. Jufang Huang contributed to data analysis, study results interpretation, and reviewing the manuscript. All authors approved the final version of the manuscript to be published.</p></ack><sec sec-type="data-availability" id="s5-1"><title>DATA AVAILABILITY</title><p>The original contributions from the present study are included in the article; further inquiries can be directed to the corresponding authors.</p></sec><sec sec-type="ethics" id="s5-2"><title>ETHICS APPROVAL</title><p>The studies involving human participants were reviewed and approved by the Ethics Committee for Clinical Trials of the First Affiliated Hospital of Xiamen University and the First Affiliated Hospital of Jinan University. The participants provided written informed consent prior to participation in this study.</p></sec><sec sec-type="supplementary-material" id="s5-3"><title>SUPPLEMENTAL MATERIAL</title><p specific-use="print-only">The following material is available online at <ext-link xlink:href="https://doi.org/10.1128/aac.00462-25" ext-link-type="uri">https://doi.org/10.1128/aac.00462-25</ext-link>.</p><supplementary-material id="SuF1" position="float" content-type="local-data" orientation="portrait"><object-id pub-id-type="doi">10.1128/aac.00462-25.SuF1</object-id><label>Table S1</label><caption><title>aac.00462-25-s0001.docx</title><p>Participants&#8217; demographic and baseline characteristics.</p></caption><media xlink:href="aac.00462-25-s0001.docx" position="float" orientation="portrait"/></supplementary-material><p specific-use="online-only">ASM does not own the copyrights to Supplemental Material that may be linked to, or accessed through, an article. The authors have granted ASM a non-exclusive, world-wide license to publish the Supplemental Material files. Please contact the corresponding author directly for reuse. </p></sec><ref-list><title>REFERENCES</title><ref id="B1"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Taubenberger</surname><given-names>JK</given-names></string-name>, <string-name name-style="western"><surname>Morens</surname><given-names>DM</given-names></string-name></person-group>. <year>2010</year>. <article-title>Influenza: the once and future pandemic</article-title>. <source>Public Health Rep</source><volume>125 Suppl 3</volume>:<fpage>16</fpage>&#8211;<lpage>26</lpage>.<pub-id pub-id-type="pmcid">PMC2862331</pub-id><pub-id pub-id-type="pmid">20568566</pub-id></mixed-citation></ref><ref id="B2"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Iuliano</surname><given-names>AD</given-names></string-name>, <string-name name-style="western"><surname>Roguski</surname><given-names>KM</given-names></string-name>, <string-name name-style="western"><surname>Chang</surname><given-names>HH</given-names></string-name>, <string-name name-style="western"><surname>Muscatello</surname><given-names>DJ</given-names></string-name>, <string-name name-style="western"><surname>Palekar</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Tempia</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Cohen</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Gran</surname><given-names>JM</given-names></string-name>, <string-name name-style="western"><surname>Schanzer</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Cowling</surname><given-names>BJ</given-names></string-name>, <etal>et al.</etal></person-group>. <year>2018</year>. <article-title>Estimates of global seasonal influenza-associated respiratory mortality: a modelling study</article-title>. <source>Lancet</source><volume>391</volume>:<fpage>1285</fpage>&#8211;<lpage>1300</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S0140-6736(17)33293-2</pub-id><pub-id pub-id-type="pmid">29248255</pub-id><pub-id pub-id-type="pmcid">PMC5935243</pub-id></mixed-citation></ref><ref id="B3"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Gaitonde</surname><given-names>DY</given-names></string-name>, <string-name name-style="western"><surname>Moore</surname><given-names>FC</given-names></string-name>, <string-name name-style="western"><surname>Morgan</surname><given-names>MK</given-names></string-name></person-group>. <year>2019</year>. <article-title>Influenza: diagnosis and treatment</article-title>. <source>Am Fam Physician</source><volume>100</volume>:<fpage>751</fpage>&#8211;<lpage>758</lpage>.<pub-id pub-id-type="pmid">31845781</pub-id></mixed-citation></ref><ref id="B4"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Fraaij</surname><given-names>PLA</given-names></string-name>, <string-name name-style="western"><surname>Heikkinen</surname><given-names>T</given-names></string-name></person-group>. <year>2011</year>. <article-title>Seasonal influenza: the burden of disease in children</article-title>. <source>Vaccine (Auckl)</source><volume>29</volume>:<fpage>7524</fpage>&#8211;<lpage>7528</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.vaccine.2011.08.010</pub-id><pub-id pub-id-type="pmid">21820476</pub-id></mixed-citation></ref><ref id="B5"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Molbak</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Espenhain</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Nielsen</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Tersago</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Bossuyt</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Denissov</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Baburin</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Virtanen</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Fouillet</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Sideroglou</surname><given-names>T</given-names></string-name>, <etal>et al.</etal></person-group>. <year>2015</year>. <article-title>Excess mortality among the elderly in European countries, December 2014 to February 2015</article-title>. <source>Euro Surveill</source><volume>20</volume>:<elocation-id>21065</elocation-id>. doi:<pub-id pub-id-type="doi">10.2807/1560-7917.es2015.20.11.21065</pub-id><pub-id pub-id-type="pmid">25811643</pub-id></mixed-citation></ref><ref id="B6"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Zou</surname><given-names>Q</given-names></string-name>, <string-name name-style="western"><surname>Zheng</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Bao</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Yu</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Wu</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Shen</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Zhou</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Zhao</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Ma</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Wu</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Shen</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Xie</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Vijaykrishna</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>Y</given-names></string-name></person-group>. <year>2020</year>. <article-title>Influenza A-associated severe pneumonia in hospitalized patients: risk factors and NAI treatments</article-title>. <source>Int J Infect Dis</source><volume>92</volume>:<fpage>208</fpage>&#8211;<lpage>213</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.ijid.2020.01.017</pub-id><pub-id pub-id-type="pmid">31978583</pub-id></mixed-citation></ref><ref id="B7"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Kondrich</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Rosenthal</surname><given-names>M</given-names></string-name></person-group>. <year>2017</year>. <article-title>Influenza in children</article-title>. <source>Curr Opin Pediatr</source><volume>29</volume>:<fpage>297</fpage>&#8211;<lpage>302</lpage>. doi:<pub-id pub-id-type="doi">10.1097/MOP.0000000000000495</pub-id><pub-id pub-id-type="pmid">28346272</pub-id></mixed-citation></ref><ref id="B8"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Takashita</surname><given-names>E</given-names></string-name></person-group>. <year>2021</year>. <article-title>Influenza polymerase inhibitors: mechanisms of action and resistance</article-title>. <source>Cold Spring Harb Perspect Med</source><volume>11</volume>:<elocation-id>a038687</elocation-id>. doi:<pub-id pub-id-type="doi">10.1101/cshperspect.a038687</pub-id><pub-id pub-id-type="pmid">32122918</pub-id><pub-id pub-id-type="pmcid">PMC8091960</pub-id></mixed-citation></ref><ref id="B9"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Ison</surname><given-names>MG</given-names></string-name></person-group>. <year>2015</year>. <article-title>Optimizing antiviral therapy for influenza: understanding the evidence</article-title>. <source>Expert Rev Anti Infect Ther</source><volume>13</volume>:<fpage>417</fpage>&#8211;<lpage>425</lpage>. doi:<pub-id pub-id-type="doi">10.1586/14787210.2015.1018183</pub-id><pub-id pub-id-type="pmid">25695406</pub-id></mixed-citation></ref><ref id="B10"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Peng</surname><given-names>Q</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Peng</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Yang</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Song</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Han</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Yan</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Qi</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Deng</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Gao</surname><given-names>GF</given-names></string-name>, <string-name name-style="western"><surname>Shi</surname><given-names>Y</given-names></string-name></person-group>. <year>2019</year>. <article-title>Structural insight into RNA synthesis by influenza D polymerase</article-title>. <source>Nat Microbiol</source><volume>4</volume>:<fpage>1750</fpage>&#8211;<lpage>1759</lpage>. doi:<pub-id pub-id-type="doi">10.1038/s41564-019-0487-5</pub-id><pub-id pub-id-type="pmid">31209309</pub-id></mixed-citation></ref><ref id="B11"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Reich</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Guilligay</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Pflug</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Malet</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Berger</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Cr&#233;pin</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Hart</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Lunardi</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Nanao</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Ruigrok</surname><given-names>RWH</given-names></string-name>, <string-name name-style="western"><surname>Cusack</surname><given-names>S</given-names></string-name></person-group>. <year>2014</year>. <article-title>Structural insight into cap-snatching and RNA synthesis by influenza polymerase</article-title>. <source>Nature</source><volume>516</volume>:<fpage>361</fpage>&#8211;<lpage>366</lpage>. doi:<pub-id pub-id-type="doi">10.1038/nature14009</pub-id><pub-id pub-id-type="pmid">25409151</pub-id></mixed-citation></ref><ref id="B12"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Hengrung</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>El Omari</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Serna Martin</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Vreede</surname><given-names>FT</given-names></string-name>, <string-name name-style="western"><surname>Cusack</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Rambo</surname><given-names>RP</given-names></string-name>, <string-name name-style="western"><surname>Vonrhein</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Bricogne</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Stuart</surname><given-names>DI</given-names></string-name>, <string-name name-style="western"><surname>Grimes</surname><given-names>JM</given-names></string-name>, <string-name name-style="western"><surname>Fodor</surname><given-names>E</given-names></string-name></person-group>. <year>2015</year>. <article-title>Crystal structure of the RNA-dependent RNA polymerase from influenza C virus</article-title>. <source>Nature</source><volume>527</volume>:<fpage>114</fpage>&#8211;<lpage>117</lpage>. doi:<pub-id pub-id-type="doi">10.1038/nature15525</pub-id><pub-id pub-id-type="pmid">26503046</pub-id><pub-id pub-id-type="pmcid">PMC4783868</pub-id></mixed-citation></ref><ref id="B13"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Stevaert</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Dallocchio</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Dess&#236;</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Pala</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Rogolino</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Sechi</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Naesens</surname><given-names>L</given-names></string-name></person-group>. <year>2013</year>. <article-title>Mutational analysis of the binding pockets of the diketo acid inhibitor L-742,001 in the influenza virus PA endonuclease</article-title>. <source>J Virol</source><volume>87</volume>:<fpage>10524</fpage>&#8211;<lpage>10538</lpage>. doi:<pub-id pub-id-type="doi">10.1128/JVI.00832-13</pub-id><pub-id pub-id-type="pmid">23824822</pub-id><pub-id pub-id-type="pmcid">PMC3807387</pub-id></mixed-citation></ref><ref id="B14"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Stevaert</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Naesens</surname><given-names>L</given-names></string-name></person-group>. <year>2016</year>. <article-title>The influenza virus polymerase complex: an update on its structure, functions, and significance for antiviral drug design</article-title>. <source>Med Res Rev</source><volume>36</volume>:<fpage>1127</fpage>&#8211;<lpage>1173</lpage>. doi:<pub-id pub-id-type="doi">10.1002/med.21401</pub-id><pub-id pub-id-type="pmid">27569399</pub-id><pub-id pub-id-type="pmcid">PMC5108440</pub-id></mixed-citation></ref><ref id="B15"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Fodor</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Te Velthuis</surname><given-names>AJW</given-names></string-name></person-group>. <year>2020</year>. <article-title>Structure and function of the influenza virus transcription and replication machinery</article-title>. <source>Cold Spring Harb Perspect Med</source><volume>10</volume>:<elocation-id>a038398</elocation-id>. doi:<pub-id pub-id-type="doi">10.1101/cshperspect.a038398</pub-id><pub-id pub-id-type="pmid">31871230</pub-id><pub-id pub-id-type="pmcid">PMC7334866</pub-id></mixed-citation></ref><ref id="B16"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Belser</surname><given-names>JA</given-names></string-name>, <string-name name-style="western"><surname>Maines</surname><given-names>TR</given-names></string-name>, <string-name name-style="western"><surname>Tumpey</surname><given-names>TM</given-names></string-name>, <string-name name-style="western"><surname>Katz</surname><given-names>JM</given-names></string-name></person-group>. <year>2010</year>. <article-title>Influenza A virus transmission: contributing factors and clinical implications</article-title>. <source>Expert Rev Mol Med</source><volume>12</volume>:<elocation-id>e39</elocation-id>. doi:<pub-id pub-id-type="doi">10.1017/S1462399410001705</pub-id><pub-id pub-id-type="pmid">21144091</pub-id></mixed-citation></ref><ref id="B17"><label>17</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Chen</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Ma</surname><given-names>Q</given-names></string-name>, <string-name name-style="western"><surname>Zhao</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Yao</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>Q</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Yang</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Deng</surname><given-names>W</given-names></string-name></person-group>. <year>2023</year>. <article-title>Preclinical study of ZSP1273, a potent antiviral inhibitor of cap binding to the PB2 subunit of influenza A polymerase</article-title>. <source>Pharmaceuticals (Basel)</source><volume>16</volume>:<fpage>365</fpage>. doi:<pub-id pub-id-type="doi">10.3390/ph16030365</pub-id><pub-id pub-id-type="pmid">36986465</pub-id><pub-id pub-id-type="pmcid">PMC10056986</pub-id></mixed-citation></ref><ref id="B18"><label>18</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Yang</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Zhan</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Lin</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Fang</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Xu</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Lin</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Lin</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Kang</surname><given-names>C</given-names></string-name>, <etal>et al.</etal></person-group>. <year>2024</year>. <article-title>Safety and efficacy of onradivir in adults with acute uncomplicated influenza A infection: a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial</article-title>. <source>Lancet Infect Dis</source><volume>24</volume>:<fpage>535</fpage>&#8211;<lpage>545</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S1473-3099(23)00743-0</pub-id><pub-id pub-id-type="pmid">38330975</pub-id></mixed-citation></ref><ref id="B19"><label>19</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Li</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Mai</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Wu</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Ding</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Huang</surname><given-names>J</given-names></string-name></person-group>. <year>2025</year>. <article-title>Single-dose tolerability and pharmacokinetics of onradivir in Chinese patients with hepatic impairment and healthy matched controls</article-title>. <source>J Clin Pharmacol</source><volume>65</volume>:<fpage>226</fpage>&#8211;<lpage>232</lpage>. doi:<pub-id pub-id-type="doi">10.1002/jcph.6134</pub-id><pub-id pub-id-type="pmid">39287964</pub-id></mixed-citation></ref><ref id="B20"><label>20</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Sun</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Frassetto</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Benet</surname><given-names>LZ</given-names></string-name></person-group>. <year>2006</year>. <article-title>Effects of renal failure on drug transport and metabolism</article-title>. <source>Pharmacol Ther</source><volume>109</volume>:<fpage>1</fpage>&#8211;<lpage>11</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.pharmthera.2005.05.010</pub-id><pub-id pub-id-type="pmid">16085315</pub-id></mixed-citation></ref><ref id="B21"><label>21</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Nolin</surname><given-names>TD</given-names></string-name>, <string-name name-style="western"><surname>Naud</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Leblond</surname><given-names>FA</given-names></string-name>, <string-name name-style="western"><surname>Pichette</surname><given-names>V</given-names></string-name></person-group>. <year>2008</year>. <article-title>Emerging evidence of the impact of kidney disease on drug metabolism and transport</article-title>. <source>Clin Pharmacol Ther</source><volume>83</volume>:<fpage>898</fpage>&#8211;<lpage>903</lpage>. doi:<pub-id pub-id-type="doi">10.1038/clpt.2008.59</pub-id><pub-id pub-id-type="pmid">18388866</pub-id></mixed-citation></ref><ref id="B22"><label>22</label><mixed-citation publication-type="book"><person-group person-group-type="author"><collab>U.S. Department of Health and Human Services</collab></person-group>. <year>2024</year>. <article-title>Guidance for industry, pharmacokinetics in patients with impaired renal function-study design, data analysis, and impact on dosing</article-title>. <publisher-name>Food and Drug Administration. Center for Drug Evaluation and Research(CDER)</publisher-name></mixed-citation></ref><ref id="B23"><label>23</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Matsushita</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Selvin</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Bash</surname><given-names>LD</given-names></string-name>, <string-name name-style="western"><surname>Astor</surname><given-names>BC</given-names></string-name>, <string-name name-style="western"><surname>Coresh</surname><given-names>J</given-names></string-name></person-group>. <year>2010</year>. <article-title>Risk implications of the new CKD Epidemiology Collaboration (CKD-EPI) equation compared with the MDRD Study equation for estimated GFR: the Atherosclerosis Risk in Communities (ARIC) Study</article-title>. <source>Am J Kidney Dis</source><volume>55</volume>:<fpage>648</fpage>&#8211;<lpage>659</lpage>. doi:<pub-id pub-id-type="doi">10.1053/j.ajkd.2009.12.016</pub-id><pub-id pub-id-type="pmid">20189275</pub-id><pub-id pub-id-type="pmcid">PMC2858455</pub-id></mixed-citation></ref><ref id="B24"><label>24</label><mixed-citation publication-type="report"><person-group person-group-type="author"><collab>International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH)</collab></person-group>. <year>2022</year>. <article-title>M10, Bioanalytical method validation and study sample analysis.</article-title></mixed-citation></ref><ref id="B25"><label>25</label><mixed-citation publication-type="report"><person-group person-group-type="author"><collab>International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH)</collab></person-group>. <year>2024</year>. <article-title>M13A, Guideline on bioequivalence for immediate-release solid oral dosage forms.</article-title></mixed-citation></ref><ref id="B26"><label>26</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Hu</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Wu</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Ding</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Peng</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Yu</surname><given-names>Z</given-names></string-name></person-group>. <year>2021</year>. <article-title>Single and multiple dose pharmacokinetics and safety of ZSP1273, an RNA polymerase PB2 protein inhibitor of the influenza A virus: a phase 1 double-blind study in healthy subjects</article-title>. <source>Expert Opin Investig Drugs</source><volume>30</volume>:<fpage>1159</fpage>&#8211;<lpage>1167</lpage>. doi:<pub-id pub-id-type="doi">10.1080/13543784.2021.1994944</pub-id><pub-id pub-id-type="pmid">34654349</pub-id></mixed-citation></ref></ref-list></back></article>
        
    </metadata>
</record>
    </GetRecord>

</OAI-PMH>